Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Not Feeling Mega-Merger Mania Even As Pharma Sales Decline

This article was originally published in The Pink Sheet Daily

Executive Summary

Patent expiries for five products drag down revenue, but biotech deals and pipeline building remain Merck’s strategy, CEO Frazier says.

Advertisement

Related Content

PCSK9s Get Boost From IMPROVE-IT; Outcomes Data Restores Faith In LDL Surrogate
Emerging Markets Earnings Roundup: Merck, Bristol Myers Squibb, Novo Nordisk (Part 12)
Emerging Markets Earnings Roundup: Merck, Bristol Myers Squibb, Novo Nordisk (Part 12)
Deal Watch: Pfizer/AstraZeneca Lead Pack Of Takeover Efforts
Cancer Checkpoint Roundup: Big Pharmas Advance Ahead of ASCO
Mylan To Catch M&A Train, But When?
New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
Merck’s Geographic Footprint Grows A Size (Or Two) With Schering Buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS077151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel